MarketVIEW Gene Therapy & Ophthalmology  ·  April 2026 edition  ·  with GeneScope Intelligence

Retinitis Pigmentosa
Gene Therapy Commercial Forecast

Retinitis pigmentosa has moved from a genetically intractable, untreatable disease to the most active gene therapy pipeline in ophthalmology outside dry AMD. Five pivotal readouts and two BLA submissions converge in an eighteen month window from 2025 to 2027, and the only question left is which modality and which genotype captures share first, and at what price. This is the independent, patient-based commercial assessment to 2040, built on VacZine Analytics' long-standing, independent authority in vaccine and infectious-disease intelligence since 2007, now extended into gene therapy through our specialist division, GeneScope Intelligence.

12+ Active Programmes 1 Approved Therapy (Luxturna) 5 Pivotal Readouts 2025-27 10-Market Forecast to 2040 Gene Replacement vs Optogenetic
Product catalogue
VAMVG004
April 2026 edition

Format
PDF + Excel model
Coverage
10 high-income markets
Programmes assessed
Luxturna + 12 pipeline
Forecast horizon
2026 to 2040
Approach
Patient-based, bottom-up
Produced with
GeneScope Intelligence
Availability
Syndicated / bespoke
~2M
People living with RP worldwide
(approx. 1 in 4,000 people)
$3.4bn
Projected 2033 RP gene
therapy revenue, base case
12+
Gene therapy programmes in
active clinical development
2025-27
Window for 5 pivotal readouts
and 2 BLA submissions
Disease background

Why retinitis pigmentosa has become a gene therapy priority

Retinitis pigmentosa is the most common inherited retinal dystrophy and, for decades, the archetype of a genetically intractable blinding disease. Understanding its heterogeneity, and the patient journey it produces, is central to understanding where, and to whom, a genotype-specific therapy can be sold.

Peer-reviewed & 2026 pipeline data

Disease overview - Retinitis pigmentosa (RP)

Retinitis pigmentosa describes a heterogeneous group of inherited retinal dystrophies characterised by progressive degeneration of rod and cone photoreceptors and the underlying retinal pigment epithelium. First systematically described in the mid nineteenth century, RP typically announces itself with nyctalopia (night blindness), usually in childhood or adolescence, followed over subsequent decades by progressive constriction of the peripheral visual field and, eventually, loss of central vision. Untreated, patients lose on average around 1.5 lines of visual acuity every five years, with many progressing to legal blindness by their forties or fifties.

Genetically, RP is extraordinarily heterogeneous. More than 80 genes have been directly implicated in non-syndromic RP, sitting within a broader set of over 200 genes now linked to inherited retinal disease as a whole. Autosomal recessive inheritance predominates (roughly half of cases), with substantial autosomal dominant and X-linked subsets, the latter, driven largely by RPGR mutations, tends to produce the most severe and earliest-onset phenotype. Around one in five to one in three cases present as syndromic disease, most commonly Usher syndrome, in which RP is accompanied by sensorineural hearing loss. This locus heterogeneity has long been the central obstacle to both diagnosis and drug development, and it is precisely why a single gene-agnostic or genotype-specific approach cannot address the whole population.

Global prevalence is estimated at approximately 1 in 4,000 people, with published estimates ranging from around 1 in 3,000 to 1 in 5,000 depending on population and case-ascertainment method. That equates to roughly 1.5 to 2 million people living with RP worldwide, including an estimated 84,000 in the United States alone. Prevalence rises materially in populations with higher rates of consanguinity, where autosomal recessive founder mutations concentrate, and the true global burden is widely believed to be undercounted: genetic confirmation still lags clinical diagnosis in most health systems, and consistent patient registries remain the exception rather than the rule.

Until 2017, management was entirely supportive, low-vision aids, complication management such as cataract and cystoid macular oedema, and genetic counselling. Voretigene neparvovec (Luxturna), approved by the FDA in December 2017 and the EMA in 2018, remains the only licensed gene therapy in the indication, but it is restricted to the biallelic RPE65 mutation subtype, an estimated 650 or so eligible patients in the United States, roughly 1% of the RP population. That leaves well over 99% of RP patients without any approved disease-modifying option, a gap that a fast-maturing pipeline of gene-replacement, gene-agnostic and optogenetic therapies is now moving to close.

2026 ~2M+ people living with RP worldwide  |  84,000 in the US  |  200+ IRD genes implicated  |  under 1% with a disease-modifying option
Product & competitor landscape

One approved gene therapy - and twelve chasing it

Retinitis pigmentosa now hosts the most active gene therapy pipeline in ophthalmology outside dry AMD. Five pivotal or near-pivotal readouts and two BLA submissions converge in an eighteen month window from 2025 to 2027 - the VacZine Analytics and GeneScope Intelligence model tracks every asset, genotype and scenario.

  • Spark Therapeutics / RocheApproved 2017
    Luxturna (voretigene neparvovec) Only licensed RP gene therapy
    Subretinal AAV2 gene-replacement vector for biallelic RPE65 mutation-associated retinal dystrophy. Approved by the FDA in December 2017 and the EMA in 2018. Reaches an estimated ~650 eligible patients in the US, around 1% of the RP population, and anchors pricing precedent for the entire indication.
  • Nanoscope TherapeuticsRolling BLA
    MCO-010 Gene-agnostic, optogenetic
    Gene-agnostic optogenetic therapy delivered by intravitreal injection, applicable regardless of causative mutation. Rolling BLA submission initiated June 2025, the first for a gene-agnostic retinal gene therapy. Three-year RESTORE/REMAIN data at ARVO 2026 showed visual-acuity gains sustained from week 52 to week 152 with no second dose, and 14 of 15 patients off inflammation treatment.
  • OcugenPhase 3
    OCU400 Gene-agnostic modifier
    NR2E3-based gene modifier therapy intended to work across multiple genotypes. Phase 3 liMeliGhT trial (n=140) completed enrolment March 2026, with topline data expected Q1 2027 ahead of a planned rolling BLA.
  • Beacon TherapeuticsPhase 3
    Laru-zova X-linked RP (RPGR)
    Subretinal AAV gene-replacement therapy for X-linked RP. Phase 2 DAWN 12-month data at ARVO 2026 showed a clean dose response: 67% of low-dose and 50% of high-dose patients gained clinically meaningful vision. Pivotal Phase 2/3 VISTA enrolment completed July 2025, topline data due H2 2026.
  • MeiraGTx / Johnson & JohnsonReacquired 2026
    Bota-vec X-linked RP (RPGR)
    Gene-replacement therapy for X-linked RP. Phase 3 LUMEOS missed its primary BCVA endpoint in May 2025, but showed clinically meaningful secondary low-luminance visual acuity gains. MeiraGTx reacquired the asset from J&J in April 2026 for roughly 6% of the original 2023 deal value, targeting global regulatory filings and a 2027 launch.
  • Second-wave pipelineVarious
    SparingVision, Ray Therapeutics, 4DMT, GenSight, PYC Therapeutics, Sepul Bio and Restore Vision
    SparingVision (SPVN06 neuroprotection and SPVN20 optogenetic), Ray Therapeutics RTx-015 (FDA RMAT designation, April 2026), 4D Molecular Therapeutics 4D-125 (intravitreal AAV for X-linked RP), GenSight GS030 (optogenetic), PYC Therapeutics VP-001 (PRPF31-associated RP, advancing toward Phase 3), Sepul Bio ultevursen (USH2A-associated RP, Phase 2b LUNA) and Restore Vision RV-001 (first-in-human chimeric-rhodopsin signal, Japan). The full report profiles all twelve-plus programmes by genotype, modality and stage.
Market inflection
H2 2026

For the first time in the history of the indication, RP patients have a realistic path to an approved disease-modifying therapy beyond the narrow RPE65 subtype. Three credible candidates, from three different modalities and regulatory routes, laru-zova, bota-vec and MCO-010, could each reach the market within a single twelve-month window, and the order of arrival is not yet decided. The VacZine Analytics and GeneScope Intelligence model quantifies the commercial consequences of every plausible sequencing scenario.

Scope of analysis

Six analytical layers - one commercial picture

The MarketVIEW retinitis pigmentosa analysis spans disease burden, genotype and modality segmentation, the full competitor pipeline and patient-based revenue forecasting across ten high-income markets to 2040.

Patient-based forecast to 2040

Bottom-up epidemiology across 10 high-income markets, with disease-stage segmentation (early-to-mid vs late-stage RP) and four age-stratified cohorts built from single-year-of-age country populations.

Competitor & pipeline review

Head-to-head assessment of Luxturna and the 12+ programme pipeline: modality, genotype, trial stage, regulatory pathway and the commercial implications of the 2025-27 readout window.

Three pricing scenarios

Low, Luxturna-anchored and high pricing cases applied consistently across all 10 markets and rolled up to global, North America, EU5 and developed rest-of-world views.

Genotype & modality segmentation

Gene-replacement, gene-agnostic modifier and optogenetic approaches modelled separately, reflecting fundamentally different addressable populations and pricing logic.

Disease burden & epidemiology

Updated global and market-level prevalence, inheritance-pattern splits, diagnosis-rate assumptions and the Usher syndrome overlap, referenced against the current peer-reviewed literature.

Value case & healthcare costs

Discussion of healthcare costs potentially averted against current standard of care, supporting payer and market-access conversations for gene therapy in inherited retinal disease.

Sample analysis

A glimpse of the commercial model

The table below shows a partial view of the genotype and scenario framework. Full revenue outputs, pricing assumptions and country-level data are in the licensed model.

Genotype / modalityDisease stageGeographyTherapy profileRevenue scenario
Biallelic RPE65 (gene replacement)All stagesUSSingle-dose subretinalModelled
X-linked RPGR (gene replacement)Early-to-midUS + EU5Single-dose subretinalModelled
Gene-agnostic (optogenetic)Late-stage10-marketSingle-dose intravitrealModelled
█████████████████████████$██m (base)
█████████████████████████$██m (upside)
Total addressable - baseGlobalAllAll profiles$███m
Full model in the licensed workbook
10 markets · disease stage · 4 age cohorts · 3 pricing scenarios
Register interest →
Deliverables

What you receive

A comprehensive intelligence package combining a detailed executive presentation and a fully interactive forecast model, built for decision-makers who need the full picture on the retinitis pigmentosa gene therapy opportunity.

  • Executive presentation (~125 slides, PDF) - disease background, epidemiology, current treatment landscape, evolving R&D pipeline and a value-case discussion of healthcare costs potentially averted versus current standard of care
  • Interactive MS-Excel forecast model - patient-based volume and revenue outputs to 2040, with editable assumptions across epidemiology, diagnosis rate, disease-stage split, country-specific uptake curves and pricing
  • Three pricing scenarios per country - low, Luxturna-anchored and high, applied across all 10 markets and aggregated to global, North America, EU5 and developed rest-of-world views
  • Competitor intelligence - Luxturna versus the 12+ programme pipeline, genotype by genotype and modality by modality, including the bota-vec reacquisition and the H2 2026 launch race
  • Updated epidemiology module - global and market-level prevalence, inheritance-pattern splits, four age-stratified cohorts and the Usher syndrome overlap
  • 10-market geographic build - USA, Canada, France, Germany, Spain, Italy, UK, Australia, Japan and South Korea, annual forecast 2026 to 2040
Target audience

Built for organisations weighing the RP opportunity

Most valuable to teams evaluating the retinitis pigmentosa gene therapy market against their own pipeline, BD ambitions or investment thesis, particularly ahead of the 2025-27 readout window.

Gene therapy developers & BD

Positioning, competitive benchmarking and partnering economics for RP candidates at any stage, genotype or modality.

Corporate strategy (large pharma)

Validate market size and structure ahead of in-licensing or bolt-on acquisition decisions in inherited retinal disease.

Investors & equity analysts

Independent assessment of market size and pipeline risk for due diligence on ophthalmology gene therapy assets.

Payers & market access

Budget-impact modelling for 2028-plus gene therapy launches in inherited retinal disease, and the healthcare-cost-averted case.

Researchers & academia

Comprehensive epidemiology, genotype landscape and pipeline mapping for grant and translational planning.

Clinicians & retinal specialists

A structured view of the evolving treatment landscape to inform patient counselling and referral pathways.

About this analysis · VAMVG004

VacZine Analytics has built independent, boutique intelligence on vaccine and infectious-disease markets since 2007. That same rigour, disease-first epidemiology paired with an independently constructed commercial model, now extends into gene therapy through our specialist division, GeneScope Intelligence. Retinitis pigmentosa is one of the first titles in that programme: a rare-disease indication with genuinely heterogeneous biology, a fast-maturing pipeline, and a commercial question, which modality and genotype wins, and at what price, that generic market sizing cannot answer.

This April 2026 edition incorporates the ARVO 2026 data readouts (laru-zova, MCO-010, RV-001) and the MeiraGTx reacquisition of bota-vec from Johnson & Johnson. The full syndicated MarketVIEW edition proceeds subject to sufficient client buy-in; where a faster or more tailored answer is required, VacZine Analytics and GeneScope Intelligence can also be commissioned to deliver bespoke, ad-hoc analysis on this market.

MarketVIEW & GeneScope Intelligence · VAMVG004 · Syndicated & bespoke

Syndicate the report - or commission the answer you need

Register your interest to help shape and secure the full syndicated MarketVIEW edition, which proceeds subject to sufficient client buy-in. Single-licence and multi-seat options follow on publication. Need something faster or more specific? VacZine Analytics and GeneScope Intelligence can be commissioned for bespoke, ad-hoc retinitis pigmentosa analysis, a briefing call is included on request.